Last reviewed · How we verify
Monacrin — Competitive Intelligence Brief
unknown
aminoacridine
Ribosyldihydronicotinamide dehydrogenase [quinone], Amine oxidase [flavin-containing] A, Trypanothione reductase
Other
Live · refreshed every 30 min
Target snapshot
Monacrin (aminoacridine). Monacrin works by inhibiting the activity of Ribosyldihydronicotinamide dehydrogenase [quinone], an enzyme that plays a crucial role in cellular energy production.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Monacrin TARGET | aminoacridine | unknown | aminoacridine | Ribosyldihydronicotinamide dehydrogenase [quinone], Amine oxidase [flavin-containing] A, Trypanothione reductase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (aminoacridine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Monacrin CI watch — RSS
- Monacrin CI watch — Atom
- Monacrin CI watch — JSON
- Monacrin alone — RSS
- Whole aminoacridine class — RSS
Cite this brief
Drug Landscape (2026). Monacrin — Competitive Intelligence Brief. https://druglandscape.com/ci/aminoacridine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing